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1. Introduction 
Although ovarian cancer is the fifth most common cancer among women, it causes more 
death than any other type of female reproductive cancer (Mørch et al., 2009). Besides 
difficulties in early detection, limited options for the treatment of ovarian cancer at late 
stages have been the major cause of high mortality rate (Jemal et al., 2003). About 76% of 
women with ovarian cancer survive 1 year after diagnosis, but only about 45% will live 5 
years after diagnosis (Choi et al., 2008). Therefore, it may be desirable to look for alternative 
means of treating this type of cancer rather than the conventional ones including chemo- or 
radiotherapy.  
During the last two decades, target-oriented antibody-based anti-cancer drugs have become 
the main stream choices for cancer treatments in humans. Although the efficacy of cancer 
treatments varies greatly with individual cases, overall improvements of patients' care and 
survival are significant, when compared to those of the conventional ones. Besides those 
approved by the FDA of the United States of America for the clinical treatments of cancer, 
numerous antibody-drug candidates are still at various stages of clinical trials and pending 
for the final approval by the FDA (Waldmann, 2003).  
Generally speaking, the majority of antibody-based anti-cancer drugs are target-oriented 
and the adverse side effects upon infusion of the antibody drugs are relatively mild as 
compared to those of the traditional ones. Therefore, selections of suitable targets against the 
tumor cells have become an essential step for the long term antibody drug development. In 
general, the ideal tumor target for the antibody drugs can be selected based on its 
accessibility, high abundance and surface homogeneity. Moreover, it should not be highly 
expressed on normal cells or tissues, especially the vital organs in humans (McGuire et al., 
1996). 
Recently, two monoclonal antibodies were identified and selected based on these criteria 
for ovarian cancer. One is RP215 which recognizes a carbohydrate-associated epitope 
found preferentially in cancer cell-expressed immunoglobulin superfamily proteins, 
designated in general as CA215. The other is GHR106 which was shown to react with the 
extracellular domain of human GnRH receptor. Both CA215 and GnRH receptor are 
widely expressed among cancer cells of different tissue origins, especially those of the 
human ovary with positive rates ranging from 60-80% (Lee et al., 2008, 2009; Lee & Ge, 
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2010a). The binding of either of these two monoclonal antibodies was found to inhibit the 
growth of ovarian cancer cells in vitro and in vivo through studies of induced apoptosis 
and complement-dependent cytotoxicity. Therefore, additional preclinical studies were 
performed to elucidate the mechanisms of action of these monoclonal antibodies as anti-
cancer drugs for the treatment of ovarian cancer. These studies should represent our 
efforts to demonstrate the potential use of these monoclonal antibodies as the anti-ovarian 
cancer drugs in the future. 
2. Results and discussion 
In this study, two monoclonal antibodies, RP215 and GHR106, were evaluated to see if they 
are suitable drug candidates for the potential treatment of ovarian cancer. Several in vitro 
and in vivo experiments were performed including (1) immunohistochemical staining and 
Western blot assay to reveal the relative abundance of target antigens, CA215 and GnRH 
receptor, respectively, each of which appears on the surface of cancer cells of the ovary, (2) 
apoptosis and complement-dependent cytotoxicity assays to demonstrate the respective 
anti-cancer efficacy of these two monoclonal antibodies, (3) elucidation of respective 
molecular mechanisms of action of RP215 and GHR106 as anti-cancer drugs through gene 
expression/regulation studies, (4) nude mouse experiments to reveal the dose-dependent 
inhibition of the growth of tumor cells and (5) construction of chimeric forms of RP215 and 
GHR106 monoclonal antibodies for future preclinical and clinical studies, (6) clinical 
evaluations of CA215 levels from serum specimens of cancer patients by using the 
established enzyme immunoassay kits, and (7) glycoanalysis to elucidate the proposed 
structure of carbohydrate-associated epitope(s) recognized by RP215 in CA215. 
2.1 Immunohistochemical studies and Western blot assay 
RP215 and GHR106 monoclonal antibodies were found to react with antigens localized on 
the surface of a variety of cancer cells including that of the ovary. By indirect 
immunohistochemical studies, it can be shown that three of the selected ovarian cancer cell 
lines, including OC-3-VGH, OVCAR-3, and SKOV-3, were strongly stained with RP215 and 
GHR106, respectively, whereas normal mouse IgG as the negative control gave little or no 
colour staining. The results of such an analysis are presented in Figure 1A (Lee et al., 1992, 
2008, 2009; Lee & Ge, 2010a). The immunohistochemical studies of selected cancerous tissue 
sections of the human ovary were also performed with RP215 as the primary antibody 
probe. The results are presented in Figure 1B for comparisons. In a separate study, GHR106 
was used as a probe to carry out immunohistochemical staining of cancerous tissue sections 
of the ovary from patients at four various stages of ovarian cancer (Chien et al., 2004). From 
the results of this analysis, it was generally concluded that the positive staining rates of 
ovarian cancer tissue sections increase with the stages of this disease (37.5% at stage I to 
100% at stage IV) (Chien et al., 2004). In contrast, the immunohistochemical staining of tissue 
sections of the normal ovary showed negative staining results. The results of such analysis 
are summarized in Figure 1C. 
The antigens recognized by RP215 and GHR106 in the cell extract of ovarian cancer cells 
were also determined by Western blot assay (Lee et al., 2008, 2009; Lee & Ge, 2010a). In the 
case of RP215, the corresponding antigen, CA215, was found to have a molecular size 
ranging from 50 to 75 kDa for the cell extract from either of the three ovarian cancer cell 
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lines (OC-3-VGH, OVCAR-3 and SKOV-3). When GHR106 was used as the probe for the 
same assay, the molecular weight of GnRH receptor of these cancer cells was found to be 60 
kDa. The results were consistent with those reported previously for human GnRH receptor 
(Lee & Ge, 2010a). The results of such analysis are presented in Figure 2. 
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Fig. 1. (A) Immunohistochemical study to reveal staining of three different ovarian cancer 
cell lines, OC-3-VGH, OVCAR-3 and SKOV-3 with RP215, GHR106 and normal mouse IgG 
(NMIgG, negative control); (B) Immunohistochemical study to reveal staining of selected 
ovarian cancer tissue sections (P-128, P-162, P107 and 525) with RP215. The areas of staining 
are highlighted with the arrows; (C) Results of immunohistochemical staining of GnRH 
receptor of ovarian tissue sections at different stages (I to IV) of ovarian cancer. n = total 
number of specimens. 
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Fig. 2. Western blot assay to reveal protein bands from the extract of three ovarian cancer 
cell lines, OC-3-VGH (1 and 4), SKOV-3 (2 and 5) and OVCAR-3 (3 and 6), respectively, 
when probed with RP215 (lanes 1, 2 and 3) as well as GHR106 (lanes 4, 5 and 6). The 
molecular weight markers of 50 kDa, 60 kDa and 75 kDa are indicated by arrows. 
2.2 Effects of RP215 and GHR106 monoclonal antibodies on the induction of 
apoptosis to ovarian cancer cells 
By using terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay, the 
induced apoptosis of cancer cells upon incubation with RP215 and GHR106 could be clearly 
demonstrated. As shown in Figure 3A, all of the three ovarian cancer cell lines were found 
to undergo significant cellular apoptosis, when incubated with 10 μg/mL of either RP215 or 
GHR106 (24 - 48 h). A significant apoptosis of cancer cells was also induced upon treatments 
with 0.1 μg/mL of a GnRH antagonist, Antide or GnRH. Under the same assay conditions, 
the chimeric form of RP215, ChRP215, was found to induce apoptosis of the OC-3-VGH  
cancer cell line, similar to that observed for murine RP215. The results of such a comparative 
analysis are also summarized in Figure 3B. Similarly, chimeric form of GHR106, ChGHR106, 
was found to have the same effects as that of GHR106 in inducing apoptosis of the ovarian 
cancer cells (Figure 3B). 
In addition to RP215, the induction of apoptosis to OC-3-VGH ovarian cancer cell has also 
been confirmed with other RP215-related monoclonal antibodies (RCA10, RCA100, RCA104, 
RCA110 and RCA111, see section 2.11), as demonstrated in Figure 3C. 
2.3 Effects of RP215 and GHR106 monoclonal antibodies on complement-dependent 
cytotoxicity of ovarian cancer cells 
The complement-dependent cytotoxicity assay was also employed to study the induction of 
complement-dependent cell lysis to OC-3-VGH ovarian cancer cells in the presence of 
complement and RP215 or GHR106 (10 μg/mL for 2 h incubation). The chimeric forms of 
monoclonal antibodies, ChRP215 or ChGHR106, also demonstrated a similar degree of 
complement-dependent cytotoxicity reaction to cultured ovarian cancer cells under the same 
conditions of incubation. In contrast, complement alone or complement with GnRH 
antagonist, Antide (0.1 μg/mL), revealed no effect on complement-dependent cytotoxicity 
to ovarian cancer cells (data not shown). Results of this complement-dependent cytotoxicity  
assay with different monoclonal antibodies plus complement are summarized in Figure 4 
for comparisons. 
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Fig. 3. (A) The TUNEL assay to demonstrate the increase in apoptosis of cancer cells in 
response to the treatment of cultured OC-3-VGH (Lanes 1-3), OVCAR-3 (Lanes 4-6) and 
SKOV-3 (Lanes 7-9) cells for 48 h with either of the following monoclonal antibodies (dose: 
10 μg/mL each): normal mouse IgG (Lanes 1, 4, 7), RP215 (Lanes 2, 5, 8) and GHR106 (Lanes 
3, 6,9), respectively; (B) The TUNEL assay to demonstrate the increase in apoptosis of OC-3-
VGH cells in response to the treatment by chimeric as well as murine monoclonal antibodies 
(dose: 10 μg/mL each) for 48 h: Lane 1: non treatment; Lane 2: normal mouse IgG; Lane 3: 
ChRP215; Lane 4: ChGHR106; Lane 5: RP215; Lane 6: GHR106; and Lane 7: 0.1 μg/mL 
Antide; (C) The TUNEL assay to demonstrate the increase in apoptosis of cancer cells in 
response to the incubation of OC-3-VGH cancer cells for 48 h with the following antibodies 
(1 μg/mL each): Lanes 1-7 correspond to that of normal mouse IgG, RCA10, RCA100, 
RCA104, RCA110, RCA111, and RP215, respectively (to be described in section 2.11). All 
data presented are statistically significant at * P < 0.05, ** P < 0.01, and ***P<0.001. 
A 
C 
B 
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Fig. 4. Complement-dependent cytotoxicity assay to demonstrate the respective effects of 
normal mouse IgG (Lane 3), ChRP215 (Lane 4), ChGHR106 (Lane 5), RP215 (Lane 6), 
GHR106 (Lane 7), and goat anti-human IgG (Lane 8) on the complement-dependent lysis of 
OC-3-VGH ovarian cells. White, monoclonal antibody (10 μg/mL) alone; Grey, monoclonal 
antibody (10 μg/ml) plus complement; Black, non-treatment (Lane 1) or 3 μL freshly 
prepared rabbit baby complement (Lane 2) as control.  * and ** indicate statistical 
significance of P<0.05 and P<0.01, respectively. 
2.4 Effects of RP215 or GHR106 monoclonal antibodies on the expression of selected 
genes in ovarian cancer cells 
Molecular mechanisms of action by which RP215 or GHR106 inhibit the growth of OC-3-
VGH ovarian cancer cells were elucidated through the studies of gene regulation by 
qualitative and semi-quantitative RT-PCR (Lee & Ge, 2010a; Kang et al., 2003; Leung et al., 
2003; Gründker et.al., 2000). A number of genes related to the growth of cancer cells were 
examined for their expressions in response to the treatment of cultured ovarian cancer cells 
with either of these two monoclonal antibodies for 48 h. The results of this qualitative 
analysis with a number of selected genes are summarized in Table 1.  
Parallel to this gene expression study, the effects of GnRH antagonist, Antide, on the 
expression of selected genes in ovarian cancer cells are also presented for comparisons with 
those of GHR106. Based on the results of this comparative analysis, it was clearly 
demonstrated that both GHR106 and Antide induce the same patterns of gene regulations to 
ovarian cancer cells upon their respective ligand binding.  
Generally speaking, the incubation of RP215 with OC-3-VGH ovarian cancer cells was found 
to increase the gene expression of IgG and NFKB1 (Li & Verma, 2002), but genes of 
ribosomal proteins, P0, P1 and P2 were significantly down-regulated (Lee & Ge, 2010b). 
RP215 incubation to cultured cancer cells were found to have no effect on EGF (epidermal 
growth factor) (Gründker et al., 2000), but caused a significant decrease in the gene 
expression of c-fos (Dragunow & Faull, 1989). On the other hand, under the same incubation 
conditions, both GHR106 monoclonal antibody and GnRH antagonist, Antide, were shown 
to up-regulate the expression of GnRH gene, but not that of GnRH receptor (Lee & Ge, 
2010b). Gene regulations of ribosomal proteins by GHR106 or Antide were also different 
from those by RP215. While P0 gene was found to be down-regulated, P1 gene was up-
regulated instead (Lee & Ge, 2010b). Although no changes in c-fos gene regulation were 
observed, EGF was found to be down-regulated significantly with the treatment of GHR106 
or Antide. The results of such a comprehensive analysis with OC-3-VGH ovarian cancer 
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cells are presented in Table 1. From this gene regulation analysis, it can be shown that the 
molecular mechanisms of action by which the apoptosis of cancer cells is induced with 
RP215 are quite different from those of GHR106 or GnRH antagonists, Antide. 
 
Gene RP215 (10 µg/ml )  GHR106 (10 µg/ml) Antide (0.1 µg/ml)
GnRH  N.Ta ↑ ↑
GnRH receptor N.T N.C N.C
IgG ↑c N.T N.T
NFKB1b ↑ N.T N.T
P0
 ↓c ↓ ↓
P1 ↓ ↑ ↑
P2 ↓ N.C N.C
EGF N.Ca ↓ ↓
c-fos ↓ N.C N.C
 
 
aN.T: not tested; N.C: not changed 
bAbbrevations used: NFKB1: nuclear factor of kappa light polypeptide gene enhancer in B cells 1; P0, P1 
and P2 are genes expressed by selected ribosomal proteins; c-fos: cellular oncogene proteins; EGF: 
epidermal growth factor. 
c↑ and ↓ indicate significant up and down gene regulations, respectively when compared to that of 
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase). 
Table 1. Gene regulation studies in cultured OC-3-VGH ovarian cancer cells using RP215, 
GHR106 and Antide. 
2.5 Expressions of immunoglobulins of different classes from ovarian cancer cells 
derived from a single clone 
OC-3-VGH ovarian cancer cells which were derived from a single clone were found to 
express IgG, IgA and IgM, simultaneously. This is in contrast with those of B cells, each of 
which expresses only a single class of immunoglobulins. (Qiu et.al., 2003; Huang et al.,2008; 
Zhang et al., 2010 ). This observation strongly suggests that immunoglobulins may be 
expressed by cancer cells through different mechanisms as compared to those of normal 
human B cells (Zheng et al., 2009). 
2.6 Nude mouse experiments 
Our previous studies have demonstrated that CA215 and GHR106 receptor are expressed on 
the surface of many human cancer cells including those of the ovary. Through in vitro 
studies with induced apoptosis and complement-dependent cytotoxicity reactions, it was 
clearly demonstrated that CA215 and GnRH receptor on the surface of cancer cells may be 
suitable targets by the respective monoclonal antibodies (Lee et al., 2009; Lee & Ge, 2010a). 
Therefore, nude mouse experiments were performed with OC-3-VGH ovarian cancer cell 
line as the model to evaluate the anti-tumor efficacy of RP215 monoclonal antibody.  
Following a single injection of three different doses of RP215 (1-10 mg/kg doses) at the time 
of tumor implantation, a significant inhibition of tumor growth was observed in a dose 
dependent manner. Fifteen days after the tumor implant and antibody treatments, the 
tumor volumes were compared. As shown in the histogram of Figure 5, the dose-dependent 
inhibition of tumor growth by RP215 was statistically significant as compared to that of the 
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negative control. In addition, I131-labelled RP215 (12 μCi/mg) was found to be more 
effective in the suppression of tumor growth than the unlabelled antibody. 
Several nude mouse experiments were also performed with models of several other cancer 
cell lines. These included: C33A (cervix) and SK-MES-1 (lung) for RP215 as well as Hep2G 
(liver) for GHR106. In each case, significant tumor reduction or inhibition of tumor growth 
was observed 14-17 days after tumor implantation and subsequent injection of antibody 
drugs (RP215 or GHR106: dose 10 mg/kg) according to similar protocols for nude mouse 
experiments as described above (data not presented). 
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Fig. 5. Tumor volumes at Day 15 were compared for nude mice treated by RP215 in 
unlabelled and I131-labelled form (specific activity 12 μCi/mg): Lane 1: negative control (no 
treatment, open column); Lane 2: positive control (black column, 60 mg/kg 
cyclophosphamide ); Lane 3: AH (antibody high dose: 10 mg/kg); Lane 4: AM (antibody 
medium dose: 5 mg/kg); Lane 5: I-AH (I131-labeled antibody high dose: 10 mg/kg); Lane 6: 
I-AM (I131-labeled antibody median dose: 5 mg/kg); Lane 7: I-AL (I131-labeled antibody low 
dose: 2 mg/kg). Data are statistically significant at *P<0.05, **P<0.01. 
2.7 Anti-idiotypic monoclonal antibodies as anti-cancer vaccines 
RP215 monoclonal antibody was shown to recognize carbohydrate-associated epitope which 
is preferentially expressed in a mixture of different glycoproteins designated as CA215 
identified in many cancer cells in humans. Polyclonal and rat monoclonal antibodies against 
the Fab-idiotypic domains of RP215 were generated and characterized (Lee et al., 2010a and 
2010b; Lee & Ge, 2010a and 2010b). The anti-idiotypic (aid) antibodies were found to bear 
the internal images of the RP215-specific carbohydrate-associated epitope. Following 
immunizations in mice with rat anti-idiotypic monoclonal antibody, the resulting anti-aid or 
Ab3 sera were found to behave like RP215 in biochemical and immunological properties 
(Lee et al., 2010a and 2010b; Lee & Ge, 2010a and 2010b).  
By Western blot assay, Ab3 antisera were found to react with protein bands identical to those 
recognized by RP215. By immunohistochemical staining study, the majority of cancer cells 
from different tissue origins were positively stained by both Ab3 antisera and RP215. Ab3 
antisera were shown to induce apoptosis, similar to that observed for RP215. Based on these 
experimental observations, it was therefore hypothesized that rat anti-idiotypic monoclonal 
antibodies or its Fab fragments bear the internal images of RP215-specific epitope (Lee et al., 
2010a and 2010b; Lee & Ge, 2010a and 2010b) and may be suitable as anti-cancer vaccines to 
induce Ab3 responses in humans for cancer treatments or preventions (Lee et al., 2010b).  
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2.8 Molecular identity of CA215 and expression of immunoglobulin superfamily 
proteins by cancer cells 
RP215 monoclonal antibody was shown to react with carbohydrate-associated epitope 
preferentially expressed by cancer cells in a mixture of glycoproteins designated as CA215. 
To reveal the molecular identity of CA215, MALDI-TOF MS (matrix assisted laser 
desorption ionization time-of-flight mass spectrometry) analysis was performed for more 
than one hundred tryptic peptides of CA215 affinity-purified from the shed medium of 
cultured OC-3-VGH ovarian cancer cells. It was generally concluded that CA215 consists 
mainly of immunoglobulin superfamily proteins (61%) including immunoglobulins (42%), T 
cell receptors (6%) and cell adhesion molecules (8%) as well as mucins (7%) and other 
unrelated ones. Results of this analysis are summarized in Table 2. 
 
 
Number of Peptides Matched
Total = 124 (Percentage)
I.  Antigen receptors
    Antibodies and immunoglobulins 52 (42.0%)
    T cell receptor chains  7 (5.7%)
II.  Antigen presenting molecules 
    MHC I and MHC II 6 (4.9%)
III. Adhesion molecules 10 (8.1%)
IV.Cytokine and growth factors 8 (6.5%)
V. Receptor tyrosine kinase/phosphatise 7 (5.7%)
VI. Others
     Immunoglobulin superfamily related (e.g. titin) 12 (9.7%)
Total with homologya: 75/124 (60.5%)
     Immunoglobulin superfamily unrelated (e.g. mucin) 9 (7.3%)
Molecular Function/Category
 
a Excluding overlapping matched peptides 
 
Table 2. MALDI-TOF MS analysis of tryptic peptides derived from affinity-purified CA215. 
By using semi-quantitative RT-PCR of the cell extract of over 20 cancer cell lines, it was 
observed that as many as 80% of these cancer cells express T cell receptors (ǂ and ǃ chains) 
at significantly high levels including OC-3-VGH, OVCAR-3 and SKOV-3 cell lines. Results 
of such an analysis are summarized in Table 3. In contrast with the exception of Raji  
(lymphoma) and Jurkat (T cell leukemia) cell lines, none of these cancer cell lines express 
CD3, CD4 and CD8 co-receptors and/or co-stimulator genes, indicating the non-functional 
nature of most of the cancer cell-expressed T cell receptors. In addition, numerous 
immunoglobulin superfamily protein-like cell adhesion molecules such as CD47, CD54, 
CD58 and CD147 are also highly expressed among all the cancer cell lines. Widespread T 
cell receptor expressions among cancer cells may have implications on cancer 
immunotherapy via T cell activation as well as the induced tolerance of T cells caused by 
tumor-associated antigens in humans (Lee et al., 2011a). 
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Origin Human Ovarian Lymphoma T-cell
 leukemia
Designation cell line SKOV-3 OVCAR-3 OC-3-VGH Raji Jurkat
ATCC NO. HTB-77 CCL-86 TIB-152
TCR (α)a +++b + ++ +++ +++
TCR (β) + ± + +++ +++
IgG (Fc) + ++ + ++ +
CD3 - - - + +
CD4 - - - - -
CD8 - - - - -
CD47 ++ ++ ++ ++ ++
CD54 ++ ++ + + ++
CD58 ++ ++ ++ ++ ++
CD147 ++ ++ ++ ++ ++  
 
a Abbreviations used: TCR, T cell receptor (ǂ chain or ǃ chain) 
b Signal intensities follow the order of +++ (strongest), ++, +, ±, - (neg), GAPDH was used as the internal 
standards. 
 
Table 3. Gene expressions of immunoglobulin superfamily proteins by RT-PCR. 
2.9 Structural elucidations of carbohydrate-associated epitope recognized by RP215 
monoclonal antibody 
In collaboration with Complex Carbohydrate Research Center at University of Georgia, 
efforts have been made to elucidate the carbohydrate-associated epitope(s) recognized by 
RP215 in CA215. (Lee & Ge, 2009). By using CA215 affinity-purified from OC-3-VGH 
ovarian and C33A cervical cancer cell lines, profiles of N-linked and O-linked glycans were 
analyzed and compared with those of other known glycoproteins from normal and 
cancerous tissues. In the case of N-linked glycans, high mannose and complex bisecting 
structures with terminal N-glycolylneuraminic acid were detected in CA215. In the case of 
O-linked glycans, several oligosaccharides were detected in CA215 with structures similar to 
those of mucins, but with terminal N-glycolylneuraminic acid. N-linked and O-linked 
glycosylation site mappings of CA215 were performed. A total of two N-linked and eight O-
linked glycopeptides were detected. Protein BLAST search of peptide sequence homology 
revealed that two N-linked and six O-linked glycopeptides were almost 100% matched to 
human immunoglobulin heavy chains. One of the remaining O-linked ones was matched to 
immunoglobulin superfamily proteins such as titin and hemicentin. Results of N-linked and 
O-linked glycosylation site mappings are summarized in Table 4. Based on the results of this 
extensive glyconanalysis, it can be suggested that both N-linked and O-linked glycans with 
unique terminal N-glycolylneuraminic acid in CA215 are structurally related to those of 
mucins. However, N-glycolylneuraminic acid might not to be directly involved in the RP215 
epitope recognition as no loss of CA215 activity was found when OC-3-VGH cells were 
cultured in medium containing human serum instead of fetal calf serum as culture medium 
supplement (Lee & Azadi, 2011). 
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Accession Number Peptide Detecteda Peptide Sequence Homology of Proteins (%)
CAC12842.1 EEQFNSTFRa Immunoglobulin heavy chain (Fc) (100%)b
CAA04843.1 EEQFNSTYR Immunoglobulin heavy chain (Fc)  (100%)
 AAB60643.2 LSVPTSEWQR Cathepsin S (100%
Hemicentin (100%)
Titin (100%)
Palladin isoform 4 (92%)
LRN4 (78%)
Immunoglobulin superfamily proteins
AAD38158.1 DTLMISR Immunoglobulin heavy chain (Fc) (100%)
AAC39746.2 GYLPEPVTVTWNSGTLTNGVR Immunoglobulin heavy chain (Fab) (90%)c
AAN76042.1 SVSLTCMINGFYPSDISVEWEK Immunoglobulin heavy chain (Fc) (90%)
CAJ75462.1 QSSGLYSLSSVVSVTSSSQPVTCNV Immunoglobulin heavy chain (Fab and Fc) (100%)
Immunoglobulin heavy chain  (Fc) (98%)
IgA variable region (89%)
IgM (98%)
Zinc finger protein 414 isoform I (100%)
Forkhead box protein C2 (100%)
Immunoglobulin heavy chain variable region (83%)
ABY48864.2 VYTMGPPREELSSR
NP_001139647.1 TFPSVR
AAK68690.1 FTCLATNDAGDSSK
 
 
 
aBold letters indicate glycosylation sites 
bFc: constant region of immunoglobulins 
cFab: variable region of immunoglobulins 
 
Table 4.  Results of N-linked and O-linked glycosylation site mappings of CA215. 
2.10 Clinical diagnostic applications of RP215-based immunoassays 
RP215 was found to recognize carbohydrate-associated epitope(s) detected preferentially 
in the cancer cell-expressed CA215, but rarely found in normal cells. This monoclonal 
antibody alone can be used in sandwich immunoassays for the determination of soluble 
CA215, if multi-RP215-specific epitope exists in a given CA215 glycoprotein molecule. 
Therefore, serum levels of CA215 can be determined quantitatively by using RP215 for 
both capturing and signal detection in a typical sandwich enzyme immunoassay. This 
enzyme immunoassay has been used in the diagnostics and monitoring of ovarian cancer 
and cervical cancers (Lee, 2009). CA215 levels in serum specimens of cancer patients at 
different disease stages can be determined by this enzyme immunoassay kit. Typical 
results of this analysis from a group of ovarian cancer patients at different stages are 
presented in Figure 6.  
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Fig. 6. Serum levels of CA215 pan cancer marker (expressed in AU/mL) for normal healthy 
individuals (NS) and for patients with ovarian cancer (OC) defined by respective stages (I, 
II, and III) of disease conditions and those with endometriosis (EM) and pelvic benign tumor 
(PET). Solid lines indicate the mean (M) serum CA215 levels in each category and dotted 
lines represent the mean values plus one standard deviation (SD). The number of cases in 
each category is indicated on the top of the scattered gram.  
Statistics: 
1. Normal control vs. ovarian carcinoma stage I (P < 0.001); stage II (P < 0.001); stage III (P 
< 0.001); stage I vs. stage III (P < 0.05); stage II vs. stage III (P > 0.05). 
2. Normal control vs. endometriosis (P > 0.05). 
3. Normal control vs. pelvic benign tumors (P = 0.05). 
Compared to the known biomarker for ovarian cancer, such as CA125, enzyme 
immunoassay for CA215 revealed a similar degree of sensitivity and specificity to those of 
the known biomarker, CA125. When both biomarkers are combined for clinical diagnosis, 
the detection sensitivity was found to increase significantly (from 68% to 87%, n=31) (Lee, 
2009). 
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Serum CA215 levels were also found to be correlated with the conditions of clinical 
treatments. It is interesting to note that the mean serum CA215 levels remained at relatively 
high levels including those at pre-operative stages and within 7 days following surgical 
operations. In contrast, serum CA215 levels decreased significantly when determined 7 days 
after the surgical operations. (Lee, 2009). 
By employing the same enzyme immunoassay kit, the clinical utility of CA215 as a pan 
cancer biomarker was evaluated with clinically defined serum specimens from over 500 
cancer patients and compared with results obtained by nine other established cancer 
biomarkers including AFP, CEA, CA215, CA19-9, CA15-3, Cyfra21, etc. (Lee et al., 2010b). A 
combination of CA215 with other tissue-associated cancer markers generally resulted in 
much higher cancer detection rates. By Western blot assay with RP215, it was revealed that 
cancer cell-expressed IgG's with RP215-specific epitope were detected in patients' serum 
specimens which were shown to have high levels of CA215 by enzyme immunoassay. In 
contrast, normal human serum specimens revealed the absence of cancer cell-expressed 
CA215 as determined by the same enzyme immunoassay (Lee et al., 2010b). 
In conclusion, RP215-based immunoassay kit may be suitable for the monitoring of cancer in 
patients including that of the ovary in terms of disease conditions as well as clinical 
treatments. 
2.11 Immunodominance of carbohydrate-associated epitope(s) recognized by RP215 
in CA215 
During our investigation of the carbohydrate-associated epitope(s) recognized by RP215, 
it was observed that the immunodominance of this unique epitope(s) in CA215 exists in 
mice. When mice were immunized with affinity-purified CA215 derived from the shed 
medium of OC-3-VGH ovarian cancer cells, only five monoclonal antibodies (RCA10, 
RCA100, RCA104, RCA110 and RCA111) were recovered from about 1000 hybridomas 
generated by cell fusion between NS-1 myeloma cells and the spleen cells from mice 
immunized with purified CA215. Unexpectedly, all five were shown to react with 
carbohydrate-associated epitope(s) which were similar to that of RP215. Judging from 
comparisons of the primary structures of these five monoclonal antibodies and RP215, 
three distinct groups of monoclonal antibodies were categorized. Group I including 
RP215, RCA10 and RCA100 were shown to have identical amino acid sequences and react 
with the linear epitope of this unique carbohydrate-associated epitope. Group II (RCA104 
and RCA111) and Group III (RCA110) monoclonal antibodies were found to recognize 
only the conformational structure(s) of this carbohydrate-associated epitope and lost their 
respective CA215 binding upon treatment with methanol or SDS. However, all the 
monoclonal antibodies were shown to exhibit common characteristics including (1) a 
decrease in CA215 binding upon the periodate treatment, (2) mutual pairing among 
monoclonal antibodies for sandwich immunoassays, and (3) loss of CA215 binding by a 
given monoclonal antibody in the presence of excess of any other monoclonal antibodies 
(Lee et al., 2011). Furthermore, all of these monoclonal antibodies were shown to induce 
apoptosis to cancer cells upon incubation with 1 μg/mL of any of these monoclonal 
antibodies as clearly demonstrated in Figure 3C. 
The reason for the existence of immunodominant carbohydrate-associated epitope(s) 
recognized by RP215 and other CA215-derived monoclonal antibodies in mice is currently 
unknown (Lee et al., 2011b). 
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2.12 Chimerization of RP215 and GHR106 monoclonal antibodies 
In order to proceed further with preclinical and clinical studies, efforts were made to 
generate human/mouse chimeric forms of RP215 and GHR106 monoclonal antibodies (Lee 
et al., 2009; Lee & Ge, 2010a). Details of this genetic engineering process including the 
elucidation of primary structures of the Fab regions of these two monoclonal antibodies 
were performed through contract research services (Avantgen, San Diego). Generally 
speaking, both the murine and chimeric forms of RP215 and GHR106 were found to have 
almost identical binding affinity to their respective antigens, CA215 and GnRH receptor, on 
the cancer cells. Successful constructions of chimeric forms of these two monoclonal 
antibodies are essential to generate humanized forms as effective anti-cancer drugs for 
treatments of human cancers including that of the ovary.  
3. Experimental procedure 
3.1 Chemicals 
All the chemicals were purchased from Sigma Chemicals Co (St Louis, MD) unless 
otherwise specified. 
3.2 Cell lines 
Human ovarian cancer cell lines, including OVCAR-3 and SKOV-3, as well as other cancer 
cell lines, including Raji and Jurkat were obtained from the American Type Culture 
Collection (ATCC), Rockville, MD, USA. All cell lines were cultured at 37 °C in a humidified 
atmosphere consisting of 5% CO2 and 95% air and maintained by subculturing cells twice a 
week according to supplier’s instructions. OC-3-VGH ovarian cancer cell lines were 
established in 1986 by Dept. OBS/GYN, Veterans General Hospital, Taipei, Taiwan. This is 
the cell line of serus origin and has been used to serve as a model for the discovery and 
studies of RP215 in our laboratory (Lee et al., 1992). This cancer cell line was maintained in 
RPMI1640 containing 10% fetal calf serum indefinitely. 
3.3 Western blot assays 
Western blot assay of cell extract from three ovarian cancer cell lines was performed according 
to the reported procedure (Lee et al., 1992; Liu et al., 1992). RP215 and GHR106 monoclonal 
antibodies were used as the respective probes to identify the molecular sites of CA215 as well 
as GnRH receptor in selected cancer cell extract. Briefly, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) was performed with cancer cell extract in the 
presence of reducing agent (ǃ-mercaptoethanol). Indirect Western blot assays were carried out 
separately by using 10 μg/mL each of RP215 or GHR106 as the respective primary antibody 
probe for 1 h incubation at room temperature. Subsequently, alkaline phosphatase (ALP)-
labeled goat anti-mouse IgG was used as the secondary antibody for an additional 1 h 
incubation. This was followed by the color development with the substrate, p-
nitrophenylphosphate purchased from Bio-Rad Laboratories (Mississauga, ON, Canada). 
Appropriate positive and negative controls as well as the molecular weight standards (BioRad 
laboratories, Mississauga, ON, Canada) were included in the routine Western blot assay. 
3.4 Immunohistochemical studies 
The immunohistochemical staining experiments were performed by using the avidin/biotin 
complex (ABC) method from Vector Laboratories (Burlingame, CA). Methanol fixed OC-3-
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VGH, OVCAR-3 or SKOV-3 ovarian cancer cells were incubated with various primary 
antibodies (RP215 and GHR106) for 2 h at 37 °C. Normal mouse IgG of the same 
concentration served as the parallel negative control. The incubation with labeled secondary 
antibodies as well as the colour staining was performed at room temperature for 1 h by 
following the protocols and instructions provided in the ABC Kits. 
3.5 TUNEL assay for assessment of cellular apoptosis 
TUNEL assay was performed to study the apoptotic effects of different monoclonal 
antibodies including RP215, ChRP215, GHR106 and ChGHR106 on cultured prostate 
cancer cells. In Situ Cell Death Detection Kit, POD (Roche, Canada) was employed for 
detection and quantitation of apoptosis at cellular levels. Briefly, OC-3-VGH, OVCAR-3 
and SKOV-3 ovarian cancer cells were cultured in RPMI 1640 medium at 37 °C in a CO2 
(5%) incubator for 24 h until all cancer cells became attached to the microwells. Selected 
antibodies of known concentrations were added separately and co-incubated for 48 h. As 
the negative control, normal mouse IgG of the same concentration (10 μg/mL) was used 
for the same incubation period. At the end of the incubation, the attached cells were 
removed from the tissue culture wells. Apoptosis of treated cancer cells were determined 
quantitatively by TUNEL assay with the instruction provided by the supplier (Gorczyca et 
al.,1993). 
3.6 Complement-dependent cytotoxicity assay 
Complement-dependent cytotoxicity assay was performed according to the standard 
protocol described previously (Lee et al., 2011a). Briefly, 1 x 105 cultured OC-3-VGH cells in 
1 mL of appropriate culture medium (RPMI 1640 with 10% FCS) were plated in 24-well 
plates for 2 h before treatment. RP215, ChRP215, GHR106, and ChGHR106 were added 
separately to give a final concentration of 10 μg/mL and incubated for 15 min at room 
temperature, respectively. Three μL of freshly prepared rabbit baby complement (CL3441; 
Cedarlane labs, Burlington, NC, USA) was added to each well followed by incubation at 
37°C for 2 h. After incubation at room temperature, the cells were recovered by 
centrifugation. Trypan blue (0.4%) (SV30084.01; Thermo Scientific, Waltham, MA, USA) was 
added and mixed gently. The percentages of cells stained with trypan blue were determined 
by cell counting under the regular microscope. Normal mouse IgG of the same 
concentration was used as the negative control. Incubation with the antibody or the 
complement alone served as the respective negative control for parallel comparisons in this 
experiment. Statistical analysis was performed to determine the significance of the assay by 
trypan blue method (Griffioen et al., 2009; Zhao et al., 2010). 
3.7 Total RNA extraction and cDNA synthesis 
Total RNA was extracted from OC-3-VGH, OVCAR-3, SKOV-3, Raji, and Jurkat cell lines 
(105-107 cells) by using QAIGEN RNeasy mini kit (Mississauga, ON, Canada) according to 
the manufacturer’s manual. Total RNA integrity and quality were checked before the 
reverse transcription. RNase-free DNase set was performed to avoid genomic gene 
interference. Reverse transcription of total RNA (0.5 μg - 5 μg/20 μL) to cDNA was 
performed by using oligo (dT)15 primer and EasyScript first strand synthesis kit from 
Applied Biological Materials Inc. (ABM)  (Richmond, BC, Canada) following the 
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manufacturer's protocol. Reaction mixtures with RNA template but without reverse-
transcriptase were used as the negative controls for cDNA synthesis. 
3.8 Semi-quantitative analysis of mRNA expressions of selected genes by RT-PCR 
All primers required for PCR amplification were obtained from Integrated DNA 
Technologies (San Diego, CA) and listed as follows:  
IgG: sense: 5’-ACGGCGTGGAGGTGCATAATG -3’; antisense: 5’- 
CGGGAGGCGTGGTCTTGTAGTT-3’; T cell receptor ǂ chain constant region: sense: 5'-
GTGCTAGACATGAGGTCTATGGAC-3' and antisense: 5'-
GGATTCGGAAGGGAATCACTGACAGG-3'; T cell receptor  ǃ chain constant region: sense: 
5’-TCTCGGCCACCTTCTGGC-3’; antisense: 5’-CATCAGCACGAGGGCACTGA-3’; CD3: 
sense: 5'-CTCTCTGGCCTGGTACTGGC-3' and antisense: 5'-
GGCTGATAGACCTGGTCATTCCTCA-3'; CD4: sense: 5' 
ACTAAAGGTCCATCCAAGCTGA-3' and antisense: 5'-
GCAGTCAATCCGAACACTAGCA-3'; CD8: sense: 5'-TTCGAGCCAAGCAGCGTCCT-3' 
and antisense: 5' CGGCACGAAGTGGCTGAAGTA-3'; CD47: sense: 5'-
GAGTGATGCTGTCTCACACAC-3' and antisense: 5'-CTCATCCATACCACCGGATCT-3'; 
CD54: sense: 5'-CGGCACGAAGTGGCTGAAGTA-3' and antisense: 5'-
CGAGGTGTTCTCAAACAGCTCCAG-3'; CD58: sense: 5’-
AGAGCATTACAACAGCCATCG-3’ and antisense: 5’-CGCTGCTTGGGATACAGGTT-3’; 
CD147: sense: 5'-CGAGGTGTTCTCAAACAGCTCCAG-3' and antisense: 5'-
CTTCCGGCGCTTCTCGTAGATG-3'; 
GnRH: sense: 5’-AACCTCTTCACCTTCTGCTGCCT-3’ and antisense: 5’-
GATTTCTTCCCAGACCCTCTTACGAG-3’; GnRH receptor: sense: 5’-
TGACACGGGTCCTTCATCAG-3’ and antisense:  5’-AAGTGGATCAAAGCATGGGTTT-
3’; NFκB: sense: 5’-CACTAAGCAGGAAGATGTGGTGGAG-3’ and antisense: 5’-
CATGGCAGGCTATTGCTCATCATGG-3;’   P0: sense: 5’-TTGTGTTCACCAAGGAGG-3’ 
and antisense: 5’-GTAGCCAATCTGCAGACAG-3’; P1: sense: 5’-
CAAGGTGCTCGGTCCTTC-3’ and antisense: 5’-GAACATGTTATAAAAGAGG-3’; P2: 
sense: 5’-TCCGCCGCAGACGCCGC-3’ and antisense: 5’-TGCAGGGAGCAGGAATT-3’; 
EGF: sense: 5’-AAGGAAATCCTCGATGAAGCCT-3’ and antisense:  5’-
TGTCTTTGTGTTCCCGGACATA -3’; c-fos: sense: 5’-GAGATTGCCAACCTGCTGAA-3’ 
and antisense: 5’-AGACGAAGGAAGACGTGTAA-3’. 
A house-keeping gene, glyceraldehyde-3-phosphate dehydrogenase was amplified and used 
as an internal control in the experiments. (Sense: 5'-GAAATCCCATCACCATCTTCC-3' and 
antisense: 5' - CCAGGGGTCTTACTCCTTGG-3'). 
PCR was performed by using 2×PCR MasterMix kit (ABM, Richmond, BC, Canada) 
according to the manufacturer’s protocols. After denaturing at 94 °C for 4 min, 20-35 cycles 
were performed under the following conditions: denaturing at 94 °C for 40 s; annealing at 58 
°C for 60 s and extension at 72 °C for 60 s. A final complete extension was then executed at 
72 °C for 7 min.  At the end, the PCR product was checked by 1.5% agarose gel 
electrophoresis. The negative control from cDNA synthesis was further used in a PCR 
reaction and served as the negative control. 
3.9 Statistical analysis 
All experiments were performed in triplicate. All the results were presented as mean ± S.D. 
Student t-test was performed to estimate the statistical significance. 
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4. Conclusion 
4.1 General conclusion 
In this chapter, two monclonal antibodies, RP215 and GHR106, were identified, 
characterized and assessed to see if they are suitable for development of antibody-based 
anti-cancer drugs. The target antigens recognized by these two monoclonal antibodies, 
CA215 and GnRH receptor, were found to be expressed on the surface of cancer cells of 
many human tissue origins including that of the ovary (Lee et al., 2008). Initially, we have 
shown by immunohistochemical studies and Western blot assays (Lee et al., 2009) that these 
two monoclonal antibodies react specifically with antigens of three cancer cell lines, OC-3-
VGH, OVCAR-3 and SKOV-3. Immunohistochemical studies with tissue sections of 87 
ovarian cancer specimens revealed that the positive staining rates with RP215 can be as high 
as 64.4% (56/87). These studies have become the basis for further preclinical studies to 
establish if these monoclonal antibodies are suitable as anti-cancer drugs for the treatment of 
ovarian cancers. 
By in vitro apoptosis assay as well as complement-dependent cytotoxicity assay, we have 
been able to show that these two monoclonal antibodies or their chimeric forms could 
induce apoptosis to ovarian cancer cells and complement-dependent cytotoxicity reactions 
upon incubation with cultured cancer cells. Furthermore, in vivo nude mouse experiments 
with implanted OC-3-VGH ovarian cancer cells revealed significant dose-dependent 
inhibition of the growth of tumor cells by RP215 (Lee et al., 2009). By using MALDI-TOF MS 
for analysis of tryptic peptides derived from affinity-purified CA215, it can be shown that 
affinity-purified CA215 consist mainly of glycoproteins including immunoglobulin 
superfamily proteins and mucins. Therefore, some of the cancer cell-expressed CA215 with 
unique carbohydrate-associated epitope recognized by RP215 seems to be critical to the 
growth of cancer cells, in vitro or in vivo (Lee et al., 2011a). 
Efforts have been made to elucidate the primary carbohydrate structures of RP215-specific 
epitope(s) in CA215 through extensive N-linked and O-linked glycoanalysis and 
glycosylation site mappings. It was generally concluded that oligosaccharides with terminal 
NeuGc with structures related to those in mucins might not be crucial in the epitope(s) 
recognition by RP215 (Lee & Azadi, 2011). 
The results of our studies have clearly demonstrated that GHR106, which reacts with the 
cancer cell-expressed GnRH receptor, can behave like a long acting GnRH analog in its 
biological actions except with a much longer half life (15-21 days) than the former (Lee & Ge, 
2010a). Similar to those of GnRH analogs, apoptosis of many human cancer cells can be 
induced for effective cancer treatments (Leung et al., 2003). In addition, complement-
dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity reactions could 
possibly be induced only with antibody-based anti-cancer drugs such as GHR106. We 
believe that the results presented in this study should provide a strong basis for these two 
monoclonal antibodies to be developed further in humans as anti-cancer drugs which might 
potentially target ovarian cancer as well as others in humans. 
4.2 Implications to the immunology of cancer cells 
It was generally postulated that certain tumor-associated antigens on the surface of cancer 
cells are overexpressed when compared with those of the normal cells (Rosenberg, 1995; 
Boon & van der Bruggen, 1996; Topalian, 1994; Lee, 2009). Their specific antibodies can be 
induced or generated to inhibit the growth of cancer cells through mechanisms of cellular 
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apoptosis, complement-dependent cytotoxicity and/or antibody-dependent cell-mediated 
cytotoxicity reactions (Oldham & Dillman, 2008; Sanz et al., 2004). These have become the 
mechanistic basis of almost all the antibody-based anti-cancer drugs currently utilized for 
clinical treatments of human cancers (Finn, 2010; Wang & Rosenberg, 1999). On the other 
hand, cancer cells can be neutralized through the mechanisms of T cell activations in vitro or 
in vivo (Wang & Rosenberg, 1999) following appropriate processes (Zou, 2006). Based on this 
principle, the first anti-prostate cancer vaccine, Provenge (Sipuleucel-T) was developed and 
approved by the US-FDA for use clinically (Kantoff et al., 2010). 
Similarly, in this study, we have explored the potential applications of RP215 and GHR106 
monoclonal antibodies as antibody-based anti-cancer drugs. In the case of RP215, the 
molecular nature of CA215 and epitope-specific oligosaccharides were elucidated. Although 
our knowledge about the immunology of cancer cells has been advanced significantly, more 
questions arising from this study needs to be addressed here. 
During the extensive molecular analysis of cancer cell-expressed CA215 with the unique 
carbohydrate-associated epitope recognized by RP215 monoclonal antibody, many 
glycoproteins involved in the normal immune system were identified and found to be 
highly expressed among many types of cancer cells, but rarely found in non-immune cells 
in humans. Among these are immunoglobulin superfamily proteins including all 
immunoglobulins, T cell receptors (ǂ and ǃ) and many cell adhesion CD molecules. The 
functional significance for the expression of these molecules in cancer cells remains to be 
explored (Lee et al., 2011a). First of all, the expression of immunoglobulins by cancer cells 
may be implicated with the existence of innate immunity in these cell types (Lee, 2009; 
Lee & Ge, 2009). Secondly, the widespread expressions of T cell receptors in cancer cells 
may also have implications in immune activations of T cells as well as the immune 
tolerance by T cells on cancer cells (Lee et al., 2011a). Thirdly, the high expression of CD-
related cell adhesion molecules may facilitate the metastasis of cancer cells (Lee et al., 
2011a). Therefore, more research work needs to be performed to resolve some of these 
puzzles.  
We believe that for cancer cells to survive under the environment of the human immune 
system, a special protective mechanism should exist among cancer cells. Therefore, much 
more effort will be required to analyze and study the "immune system" of cancer cells, 
before any effective immuno-therapy of cancer cells can be achieved (Zou, 2006; Horna & 
Sotomayor, 2006). 
Another question which needs to be addressed is the preferential attachment of RP215-
specific carbohydrate-associated epitope(s) in cancer cell-expressed CA215. In the case of 
immunoglobulin superfamily glycoproteins, the common, but special glycosylations sites 
might be generated from the conserved and common domain structures of these types of 
molecules as reported previously (Lee & Azadi, 2011). Mucin proteins, on the other hand, 
are known to consist of glycosylation sites which are favorable for the unique epitope 
attachments. However, it is equally difficult to explain the preferential absence of the RP215 
recognition sites among the same proteins in normal cells. We believe that the unique 
RP215-specific epitope(s) is the result of aberrant expressions of certain glycosyltransferases 
(Yang et al., 1994; Brockhausen, 2000), which are common to all cancer cells. This question 
can be answered only when the carbohydrate moieties of the epitope(s) structures are 
completely elucidated in the future (Lee and Azadi, 2011). 
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In this study, two potential antibody-based anti-cancer drugs were introduced and pre-
clinical studies were performed. In view of the high and widespread expressions of the 
target antigens, namely, CA215 and GnRH receptor among ovarian cancer cells, we are 
optimistic about their potential in treating ovarian cancers following appropriate research, 
development and clinical trials in the near future.  
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